,Response,Percentage of glaucoma market
0,Oral carbonic anhydrase inhibitors and other,2%
1,Topical carbonic anhydrase inhibitors,5%
2,Alpha agonist,10%
3,Fixed combo,14%
4,Beta blocker,13%
5,Latanoprost**,41%
6,Travatan Z**,6%
7,Lumigan**,7%
